Further preclinical studies are needed to determine the clinical applicability of HMGCLL1 or CDK4/6 inhibition in CML to improve DMR rates and enhance LSCs eradication. Here, HMGCLL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.